AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Juncture Use Authorization (EUA) for AZD7442, its long- production antibody…
Category Business
Read More
Pfizer and BioNTech receive CHMP positive opinion for COVID-19 vaccine booster in the European Union
Pfizer and BioNTech today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion…
Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD
Survey of Over 1,000 Asthma and COPD Patients Conducted in Partnership with AAFA Finds Symptoms are Disruptive to Daily Lives for Majority of Respondents Despite…
University of Oxford and Oracle Cloud System helping researchers identify COVID-19 variants faster
The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this…
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection
Study Now Enrolling Participants Who sleep in an equivalent Household as Someone With Symptomatic, Laboratory-Confirmed COVID-19 Merck ,known as MSD outside the us and Canada,…
Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
New data show pre-symptomatic babies with spinal muscular atrophy (SMA) treated with Evrysdi maintained the power to swallowEvrysdi has demonstrated consistent clinically meaningful efficacy in…
Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients
Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the…
Lilly Announces the first Tender Results of Its Pending Cash offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059
Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its outstanding debt…
Lilly Announces Cash offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities
Eli Lilly and Company (NYSE: LLY) announced today that it’s commenced a cash offer for up to $1.5 billion combined aggregate principal amount (the “Tender…